SCHEMBL5745809

SCHEMBL5745809

CCCCC(OC(C)=O)C(=O)CCC

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CA2 P00918 5/20 0.36
LMNA P02545 2/20 0.36
CA1 P00915 2/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPK1 P28482 1/20 0.35
CES1 P23141 1/20 0.34
CES2 O00748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744404 0.88 TSHR (0.36) PRKCAALDH1A1LMNACYP3A4TSHR
SCHEMBL5744405 0.82 TSHR (0.37) PRKCAALDH1A1TSHRCES1CES2
SCHEMBL5745716 0.82 ALDH1A1 (0.41) PRKCAALDH1A1CA2LMNACA1
SCHEMBL23175068 0.80 TSHR (0.36) PRKCAALDH1A1TSHRCES1CES2
SCHEMBL2481440 0.80 CA2 (0.47) PRKCAALDH1A1CA2CA1TDP1
SCHEMBL14575517 0.80 CA2 (0.47) PRKCAALDH1A1CA2CA1TDP1
SCHEMBL8694994 0.80 CA2 (0.47) PRKCAALDH1A1CA2CA1TDP1
SCHEMBL5355975 0.78 ALDH1A1 (0.39) PRKCAALDH1A1CA2CA1TSHR
SCHEMBL5355970 0.78 ALDH1A1 (0.39) PRKCAALDH1A1CA2CA1TSHR
SCHEMBL28023394 0.77 CA1 (0.53) PRKCAALDH1A1CA2LMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358144-B1 EPOTHILONE SYNTHESIS COMPONENTS I: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE AND EPOTHILONE DERIVATIVES R & D BIOPHARMACEUTICALS (DE) 2006-12-27 EP disclosed
US-6867333-B2 EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES MORPHOCHEM AG (DE) 2005-03-15 US disclosed
US-20040082651-A1 Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives R & D BIOPHARMACEUTICALS GMBH (DE) 2004-04-29 US disclosed
EP-1358144-A1 EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES Morphochem AG (DE) 2003-11-05 EP disclosed
WO-2002032844-A2 EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES MORPHOCHEM AG (DE) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082651-A1 Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives COASY, ACOX1, FDFT1 PRKCA 2181/4885ALDH1A1 1538/4885CA2 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.